The Conversation (0)
Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update
Mar. 07, 2018 08:28AM PST
Genetics Investing
Editas Medicine (NASDAQ:EDIT), a leading genome editing company, today reported financial results for the fourth quarter and full year 2017. The Company also outlined its recent achievements and anticipated progress as well as short- and long-term goals. As quoted in the press release: “Our accomplishments in 2017 provide strong momentum into 2018 and beyond as …
Editas Medicine (NASDAQ:EDIT), a leading genome editing company, today reported financial results for the fourth quarter and full year 2017. The Company also outlined its recent achievements and anticipated progress as well as short- and long-term goals.
As quoted in the press release:
“Our accomplishments in 2017 provide strong momentum into 2018 and beyond as we work to bring transformative medicines to patients,” said Katrine Bosley, President and Chief Executive Officer of Editas Medicine. “We advanced our lead experimental medicine, EDIT-101, toward the clinic, made important progress on multiple additional ocular and engineered cell medicine programs, and further strengthened our business with key new team members and strategic business development. We are well positioned to achieve our EM22 five-year goals, which include having five medicines in clinical development in 2022.”